XSTOCMH
Market cap211mUSD
Dec 23, Last price
10.10SEK
1D
-19.52%
1Q
-58.74%
IPO
943.39%
Name
Chordate Medical Holding publ AB
Chart & Performance
P/E
—
P/S
2,404.44
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
463.36%
Rev. gr., 5y
0.65%
Revenues
976k
+799.66%
Net income
-29m
L+4.45%
CFO
-27m
L+9.14%
Profile
Chordate Medical Holding AB (publ), a medical technology company, develops products and solutions for the treatment of chronic migraine and rhinitis in Sweden. It focuses on the ear-nose and throat area. The company was founded in 2005 and is based in Kista, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 976 799.66% | 109 -87.70% | 882 42.72% | ||||||
Cost of revenue | 1,654 | 21,124 | 15,724 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (678) | (21,015) | (14,842) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (81) | 25 | |||||||
Tax Rate | |||||||||
NOPAT | (678) | (20,934) | (14,866) | ||||||
Net income | (29,187) 4.45% | (27,943) 28.38% | (21,766) 10.16% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 33,200 | 65 | 35,077 | ||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1 | ||||||||
Net debt | (8,546) | (3,758) | (29,061) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (27,263) | (24,979) | (20,336) | ||||||
CAPEX | (378) | (389) | (1,301) | ||||||
Cash from investing activities | (1,158) | (389) | (1,301) | ||||||
Cash from financing activities | 33,200 | 65 | 35,077 | ||||||
FCF | (796) | (21,064) | (14,606) | ||||||
| Balance | |||||||||
Cash | 8,455 | 3,676 | 28,979 | ||||||
Long term investments | 91 | 82 | 82 | ||||||
Excess cash | 8,497 | 3,752 | 29,017 | ||||||
Stockholders' equity | 345,604 | (248,072) | 39,428 | ||||||
Invested Capital | 6,589 | 259,145 | 9,934 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 224,513 | 415 | 171,970 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 559 | (18,562) | (13,301) | ||||||
EV/EBITDA | |||||||||
Interest | 7 | 81 | 25 | ||||||
Interest/NOPBT | |||||||||